http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zai+Lab+Ltd+++++++++++++++For%3A+Jun+17/26659864.html si-local-file:///var/storage/secattach/20260617/26659864.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zai+Lab+Ltd+++++++++++++++For%3A+Jun+17/26659864.html Wed, 17 Jun 2026 16:06:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zai+Lab+Ltd+++++++++++++++For%3A+Jun+17/26659864.html si-local-file:///var/storage/secattach/20260617/26659864.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zai+Lab+Ltd+++++++++++++++For%3A+Jun+17/26659864.html Wed, 17 Jun 2026 16:06:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zai+Lab+Ltd+++++++++++++++For%3A+Jun+17/26659864.html si-local-file:///var/storage/secattach/20260617/26659864.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zai+Lab+Ltd+++++++++++++++For%3A+Jun+17/26659864.html Wed, 17 Jun 2026 16:06:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/Corporate+News/ZAI+LAB+wins+EMA+orphan+drug+status+for+lung+cancer+treatment/26650280.html <p>Zai Lab Limited (NASDAQ: ZLAB) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to zocilurtatug pelitecan, also known as zoci, for the treatment of pulmonary neuroendocrine carcinomas (NECs).</p><p>The designation followed a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP), which cited preliminary clinical data suggesting zoci may offer more favorable effects than currently authorized therapies in patients with relapsed or refractory extensive-stage small cell lung cancer (SCLC), including durable responses. The COMP characterized this as a clinically relevant advantage.</p><p>SCLC is the most significant pulmonary NEC, accounting for approximately 15% of the roughly 2.5 http://www.streetinsider.com/Corporate+News/ZAI+LAB+wins+EMA+orphan+drug+status+for+lung+cancer+treatment/26650280.html Tue, 16 Jun 2026 07:01:19 -0400 ZLAB http://www.streetinsider.com/FDA/ZAI+LAB+wins+EMA+orphan+drug+status+for+lung+cancer+treatment/26650280.html <p>Zai Lab Limited (NASDAQ: ZLAB) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to zocilurtatug pelitecan, also known as zoci, for the treatment of pulmonary neuroendocrine carcinomas (NECs).</p><p>The designation followed a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP), which cited preliminary clinical data suggesting zoci may offer more favorable effects than currently authorized therapies in patients with relapsed or refractory extensive-stage small cell lung cancer (SCLC), including durable responses. The COMP characterized this as a clinically relevant advantage.</p><p>SCLC is the most significant pulmonary NEC, accounting for approximately 15% of the roughly 2.5 http://www.streetinsider.com/FDA/ZAI+LAB+wins+EMA+orphan+drug+status+for+lung+cancer+treatment/26650280.html Tue, 16 Jun 2026 07:01:19 -0400 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB